Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.
